阿哌沙班与华法林在晚期慢性肾脏病合并心房颤动患者中的比较
基于ARISTOTLE试验中269例肌酐清除率25-30 mL/min的心房颤动患者,比较阿哌沙班与华法林的安全性。阿哌沙班较大出血风险更低(HR 0.34,95%CI 0.14-0.80),且药代动力学暴露范围与肾功能较好者重叠,支持该人群常规剂量使用。
要点
- 肌酐清除率25-30 mL/min房颤患者中,阿哌沙班较大出血风险低于华法林。
- 阿哌沙班5mg每日两次在该人群的暴露范围与肾功能较好者重叠。
- 该人群使用阿哌沙班的安全性与有效性仍需随机对照研究验证。
核心结论
- 在肌酐清除率25-30 mL/min的房颤患者中,阿哌沙班所致出血少于华法林,且出血减少幅度大于肌酐清除率>30 mL/min者。
研究设计与样本
- 基于ARISTOTLE试验的回顾性分析,纳入269例肌酐清除率25-30 mL/min的房颤患者。
- 采用Cox比例风险模型估计大出血及大出血或临床相关非大出血的风险比。
- 采用非线性混合效应模型评估阿哌沙班的药代动力学暴露。
主要发现
- 肌酐清除率25-30 mL/min患者中,阿哌沙班较大出血风险比为0.34(95%CI 0.14-0.80)。
- 大出血或临床相关非大出血风险比为0.35(95%CI 0.17-0.72)。
- 与肌酐清除率>30 mL/min者相比,该人群大出血风险降低趋势的交互P=0.08,大出血或临床相关非大出血的交互P=0.05。
- 阿哌沙班5mg每日两次在肌酐清除率25-30 mL/min者的稳态AUC中位数为5512 ng/(mL·h),>30 mL/min者为3406 ng/(mL·h)。
- 阿哌沙班2.5mg每日两次在肌酐清除率25-30 mL/min者的暴露中位数为2780 ng/(mL·h)。
关键数值与推荐
- 晚期慢性肾脏病定义为肌酐清除率25-30 mL/min。
- 阿哌沙班5mg每日两次在肌酐清除率25-30 mL/min者的AUC值落在>30 mL/min者所示范围内。
临床怎么用
- 肌酐清除率25-30 mL/min的房颤患者使用阿哌沙班常规剂量有药代动力学证据支持。
- 该人群使用阿哌沙班出血风险低于华法林。
- 尚需随机对照研究评估阿哌沙班在晚期慢性肾脏病(包括透析)患者中的安全性与有效性。
局限性
- 为ARISTOTLE试验的事后分析,样本量有限(269例)。
- 缺乏针对晚期慢性肾脏病(包括透析)患者的随机对照研究数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Compared with the general population, patients with advanced chronic kidney disease have a >10-fold higher burden of atrial fibrillation. Limited data are available guiding the use of nonvitamin K antagonist oral anticoagulants in this population. METHODS: We compared the safety of apixaban with warfarin in 269 patients with atrial fibrillation and advanced chronic kidney disease (defined as creatinine clearance [CrCl] 25 to 30 mL/min) enrolled in the ARISTOTLE trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). Cox proportional models were used to estimate hazard ratios for major bleeding and major or clinically relevant nonmajor bleeding. We characterized the pharmacokinetic profile of apixaban by assessing differences in exposure using nonlinear mixed effects models. RESULTS: Among patients with CrCl 25 to 30 mL/min, apixaban caused less major bleeding (hazard ratio, 0.34 [95% CI, 0.14-0.80]) and major or clinically relevant nonmajor bleeding (hazard ratio, 0.35 [95% CI, 0.17-0.72]) compared with warfarin. Patients with CrCl 25 to 30 mL/min randomized to apixaban demonstrated a trend toward lower rates of major bleeding when compared with those with CrCl >30 mL/min (P interaction=0.08) and major or clinically relevant nonmajor bleeding (P interaction=0.05). Median daily steady-state areas under the curve for apixaban 5 mg twice daily were 5512 ng/(mL·h) and 3406 ng/(mL·h) for patients with CrCl 25 to 30 mL/min or >30 mL/min, respectively. For apixaban 2.5 mg twice daily, the median exposure was 2780 ng/(mL·h) for patients with CrCl 25 to 30 mL/min. The area under the curve values for patients with CrCl 25 to 30 mL/min fell within the ranges demonstrated for patients with CrCl >30 mL/min. CONCLUSIONS: Among patients with atrial fibrillation and CrCl 25 to 30 mL/min, apixaban caused less bleeding than warfarin, with even greater reductions in bleeding than in patients with CrCl >30 mL/min. We observed substantial overlap in the range of exposure to apixaban 5 mg twice daily for patients with or without advanced chronic kidney disease, supporting conventional dosing in patients with CrCl 25 to 30 mL/min. Randomized, controlled studies evaluating the safety and efficacy of apixaban are urgently needed in patients with advanced chronic kidney disease, including those receiving dialysis. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT00412984.
引用
- Stanifer JW, Pokorney SD, Chertow GM, et al. Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. Circulation. 2020. PMID: 32160801. doi:10.1161/CIRCULATIONAHA.119.044059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。